Treatment Success for Immunocompromised Herpes Patients
The BioAlliance Pharma trial for acyclovir Lauriad just reported positive results from its phase III of testing. The trial treated immunocompromised patients (for example, people with HIV) who suffer from recurrent bouts of oral herpes, or cold sores.
Researchers found that just a single dose of the acyclovir Lauriad tablet reduced the duration of the outbreak, and delayed the time until the next outbreak occurred.
Early treatment was cited as a key to the treatment's success. No major side effects were reported.